ADC Therapeutics S.A. (ADCT) Eyes Billion Dollar Opportunity with ZYNLATA Indication Expansion

ADC Therapeutics S.A. (NYSE:ADCT) is one of the best performing penny stocks to buy now. On September 3 at the Cantor Global Healthcare Conference 2025, the company reiterated that it remains focused on expanding ZYNLATA’s use in DLBCL, aiming to establish it as a standard of care.

The company is progressing with a Phase 3 study that will evaluate the effectiveness of ZYNLATA plus rituximab as a second-line treatment for Diffuse Large B-Cell Lymphoma (DLBCL). While the study is fully enrolled, data readout and submission to the Food and Drug Administration are anticipated within the next six to twelve months. Additionally, the company is progressing in a Phase II study evaluating ZYNLATA plus Roche’s glafitamab.

The clinical trials are part of an effort that ADC Therapeutics is using to position ZYNLAT as a standard for patients ineligible for CAR-T therapy. The company is staring at tremendous opportunities, given that the market of DLBCL patients not receiving CAR-T is valued at over a billion dollars.

ADC Therapeutics S.A. (NYSE:ADCT) is a Swiss biotechnology company that discovers, develops, and commercializes targeted Antibody Drug Conjugates (ADCs) for cancer treatment. It uses proprietary pyrrolobenzodiazepine (PBD)-based technology to attach highly potent chemotherapy agents to antibodies that specifically target cancer cells.

While we acknowledge the potential of ADCT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Healthcare Penny Stocks to Buy Now and 11 Best AI Stocks to Buy Under $5

Disclosure: None. This article is originally published at Insider Monkey.